Daclizumab is a humanized IgG1 antibody raised against the α-chain of the human IL-2 receptor (CD25). In 1997, it was first approved for renal allograft rejection and showed a favorable adverse ...

The EMA had also previously advised against using daclizumab in patients with pre-existing hepatic disease or hepatic impairment, or patients with autoimmune diseases other than MS. They had also ...

And although AbbVie managed to get Zinbryta (daclizumab) on the market with partner Biogen for multiple sclerosis, earlier this year the companies withdrew it because of a risk of serious brain ...

What Are Treatments for Uveitis? Uveitis is the inflammation of your uvea — the middle layer of your eye. It can happen for many reasons, but up to 70% of cases have unknown causes. It can ...

It is important to isolate immune subsets, as demonstrated by daclizumab and fingolimod. Therefore, the treatment propagates its beneficial effects and prevents unwanted ones. In a wide range of ...